Prothrombin Complex Concentrate (PCC) is a medication that treats bleeding disorders resulting from deficiencies in coagulation factors II, VII, IX, and X. It is derived from human plasma and has concentrated coagulation factors. Administered intravenously, PCC quickly replenishes the coagulation factors in the bloodstream and helps restore normal clotting function. PCC is used to manage bleeding in patients with hemophilia, liver disease, other bleeding disorders, and emergencies such as trauma or surgery.
The market for Prothrombin Complex Concentrate (PCC) could grow significantly because of the use of Warfarin. Warfarin is a common treatment for blood clots that is also known to increase bleeding risk. PCC can be used to swiftly replace the coagulation factors in the blood and restore normal clotting function in cases of severe bleeding brought on by Warfarin. Patients on Warfarin are thus in high demand for PCC, and as a result, the market for PCC is anticipated to grow significantly. According to a study that appeared in the journal Thrombosis Research, more than 30 million prescriptions for Warfarin are reportedly generated each year in the U.S. alone. This demonstrates the pervasiveness of warfarin use as a medication and emphasizes the significance of maintaining its safe and efficient use by adopting a national action plan for drug event presentation.
Personalized medicine is expanding in the prothrombin complex concentrates industry, with businesses creating specialized treatments to address the requirements of different patients. This covers specialized goods for people with bleeding diseases and precise medicines for addressing certain genetic flaws. New delivery techniques, such as intranasal and subcutaneous systems, are also being developed to make treatment more practical and aid patients in following their treatment plan. For instance, in August 2022, CSL, a major global biotechnology company, marked the acquisition of Vifor Pharma and its range of products, including treatments for nephrology and rare diseases and kidney dialysis therapies, and iron deficiency. In January 2019, Grifols S.A. acquired the U.S. division of Biotest Pharmaceuticals Corporation to strengthen its presence in North America. This acquisition was expected to provide Grifols access to biotests plasma collection centers, thereby increasing the supply of plasma proteins for therapeutic use.
The market for prothrombin complex concentrates is growing globally, with North America holding a significant share owing to major manufacturers and the approval of a 4-factor PCC drug. In Europe, there is a growing use of 4-factor PCC products and favorable policies for reimbursement of medical expenses.
Acquired Coagulation Factor Deficiency
Congenital Coagulation Factor Deficiency
Hospital & Ambulatory Surgical Centers
Rest of Europe
Rest of APAC
Rest of LATAM
MEA (Middle East and Africa)
Rest of MEA
Takeda Pharmaceutical Company Limited.
Taibang Biological Group Co., Ltd.
Abeona Therapeutics Inc.
NEED A CUSTOM REPORT?
We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities. Contact us now
ESOMAR & Great Work to Place Certified
ISO 9001:2015 & 27001:2022 Certified
"The quality of research they have done for us has been excellent."